Subscribe to the newsletterForward | Contact | www.lyonbiopole.com   February 2014
 
A LA UNE
02/17/2014 - Success for the presentation of the 2014 international action plan

On Friday 7th of February, Lyonbiopole and I-care, the regional cluster on medical Technology, successfully presented their 2014 International action plan for their SMBs’ members. A panel of 10 trade missions covering 3 major markets (Europe, US and Asia) are proposed to the Rhone-Alps SMBs in 2014. The 1st semester is packed with major trade missions with in April an ICT – Health mission in Boston, in May another mission in China and in June the participation to the major BIO International Convention in San Diego, US.

02/11/2014 - Success for Bioinformatics and digital tools for health products day

With over 200 participants, the event, organised by INRIA and Lyonbiopole, was intended to demonstrate the interaction between the modeling, analysis and data management to improve the capacity to make further assumptions, to produce new models and compare them to experiment to develop health products. The morning was devoted to plenary interventions on the contribution of these therapies. Followed, 25 demonstrations of innovative technologies from Inria and Lyonbiopole SMBs. Finally, in the afternoon, members of Lyonbiopole presented their innovative technologies to a panel of researchers, specialists from the industrial, medical, scientific or institutional.

Learn more


06/06-05/2014 - Submit your application for BIOVISION's Catalyzer and Investor Conference


During the Forum BIOVISION 2014, which will be held on June 5-6, 2014 in Lyon, Lyonbiopole will co-organize for the second consecutive year the two sessions “Catalyzer” and “Investor Conference”. BIOVISION Catalyzer offers the opportunity to present collaborative projects and initiatives during the forum in order to gain visibility and identify potential partners. Further information and application here. BIOVISION Investor Conference facilitates meetings between entrepreneurs and investors, including business pitches before a panel of international investors. Further information and application here.

Learn more



ZOOM SUR
Alaxia

Alaxia, Lyonbiopole’s member, is an innovative biotechnology company focusing on the development of new therapies to deal with the most serious respiratory diseases. ALX-009, the candidate treatment developed by Alaxia acts on severe respiratory infection with a combination of molecules from the innate defense system. bpifrance invests over 10 million euros in the ALIPEX program seeks to provide cystic fibrosis (CF) patients with a new - generation inhalation treatment efficient in fighting severe respiratory infections, including those resistant to antibiotics. Alaxia as leader of the consortium carried out by two others companies: Eveon, DTF Medical with two research laboratories. Supported by the STRAGEN Group, a pharmaceutical shareholder, Alaxia, Eveon and DTF Medical are pooling their resources to bring ALX-009 to market as quickly as possible. 

Learn more



A LA UNE
03/07/14 - Call for innovative technological offers R&D or collaborative projects ideas

Gain in visibility by proposing your innovative technological offer or collaborative projects idea before Friday 7th, march 2014 at 5:00 p.m. on line. Selected proposals will be presented during the 2014 CASyM Academic/Industry interaction workshop which takes place in Lyon (FRANCE) on April 10th 2014CASyM (Coordinating Action Systems Medicine) is a European project, supported by the FP7- Directorate-General for Research and Innovation of the European Commission, to develop a road map outlining an integrative strategy for the implementation of systems medicine across Europe. This roadmap is used by the European Commission to help define the calls of its Horizon 2020 program.
Contact: Estelle VINCENT, Project Manager
estelle.vincent@lyonbiopole.com

03/25-26/14 - Join the Boston collective mission in the context of Bio-IT

Lyonbiopole in partnership with the other french Life science Clusters and Ubifrance and with the support of the French ministry of industry is organizing a trade mission during BIO-IT in April in Boston, the conference of ICT in Life science. On top of their participation to BIO-IT, the participant will have the chance to meet with major US players in computational Biology and e-health like the Dana Farber Cancer Institute or IBM research.
Contact : Simon Gudin - SME's Development Project Manager
simon.gudin@lyonbiopole.com

Learn more


05/4-9/14 - Join the mission in China

For the 3rd year, Lyonbiopole in partnership with Ubifrance and with the support of the Rhone-Alps regional council is organizing a trade mission in China from the 4th to the 9th of Mai 2014. The mission is focusing on market entry and identification of potential partner with the organization of 2 days of B2B in Beijing, the participation to the Sino-European BioPartnering Event in Shanghai and depending of the company interest 2 days of B2B agenda in Shanghai or the participation to ChinaBio organize by EBD in Suzhou.  
Contact : Simon Gudin - SME's Development Project Manager simon.gudin@lyonbiopole.com

Learn more


06/05-06/14 - Alain Mérieux presents BioVision 2014

 Discover his interview about Biovision 2014. BIOVISION, the World Life Sciences Forum, is becoming a yearly event. The 9th edition will be held on June 5-6, 2014 in Lyon, France. BIOVISION is the place where key stakeholders can debate over the impact of the latest scientific advances on society and share a prospective vision on how to overcome Health, Environment and Nutrition challenges. In 2014, 2 main focus will be adressed: "Vaccines and Immunotherapies" and "Healthy Ageing ".

Learn more


06/23-24/14 - Join BIO San Diego

Be part of the world largest biotech convention : BIO San Diego 2014, from the 23rd to the 26th of June 2014. Thanks to the support of the Rhone-Alps regional council, and locals administrations – Only Lyon, Grenobles Alps Metropole, and Lyon Chamber of Commerce, Lyonbiopole offer to its SMB members a tailor-made package for their participation to BIO San Diego 2014. Lyonbiopole's support includes financial support, broader visibility with the opportunity to be exhibitor on Lyonbiopole booth based on the French Pavilion and dedicated communication tools for the event.
Contact : Simon Gudin - SME's Development Project Manager simon.gudin@lyonbiopole.com

Learn more


10/28/14 - Galien International Price 2014



The Galien International Price awarded each year to recent therapeutic innovations available to the public and pharmaceutical research. It helps to promote and stimulate research on medicines and to encourage laboratories and the teams that advance.
Contact : Kevin Romani - SME's Development Director kevin.romani@lyonbiopole.com 

Learn more



AGENDA
Bio-Europe Spring 2014
March 10th to 12 th 2014 -Turino, Italia
Meet in Italy for life Sciences The future evolution of the healthcare system players
2nd april 2014 
Bio-IT World Conference & Expo'14
April 29th to may 1st 2014 - Boston, US
The 16th Shangai International Forum on Biotechnology and Pharmaceutical Industry
May 21th to 23th 2014 - Shanghai, China
BIO 2014
June 23th to 26th 2014 - San Diego, US
 
A LA UNE
03/02/14 - 04/19/14 - 6th Call for proposal is open


Universal Biotech and its partners are proud to announce that the call for proposal for the 6th edition of the Innovation Prize is now open! The prize rewards innovative projects in the following fields: Drugs, Biologics, Medical Devices, Medical Technologies and e-health solutions. Last year it rewarded Professor Richard Pleass from the Liverpool School of Tropical Medicine and his Hexagard projectThe call for proposal is open to academic researchers and young SMEs (under 10 years). Registration is now available online.

Learn more


12/11/2013 - Publication of the 1st Horizon 2020 calls for projects

The European Commission has published on December 11th 2013 the first Horizon 2020 calls for projects, the new European funding program for research and innovation with a budget of €80 billion, of which more than 15 billion euros for the first two years. The program has three pillars: scientific excellence, nearly 3 billion euros planned, including 1.7 billion for grants for top researchers; industrial leadership: € 1.8 billion are provided to support the industrial leadership of Europe in areas such as biotechnology, nanotechnology, and the societal challenges: € 2.8 billion is dedicated for innovative projects on the 7 social issues including H2020 health. Find all calls on the official portal.
Lyonbiopole supports you for EU project set-up thanks to its ETP programme.
Contact: Emilie Romeo - Europe Project Manager
emilie.romeo@lyonbiopole.com

Learn more


10/2013 - New Eurostars 2 call for projects

After the success of the 1st Eurostars programme, the EC launches Eurostars 2. This funding programme is fully dedicated to innovative SMEs aiming to launch R&D projects closed to the market, that are collaborative and European (at least 2 partners from EU). The funding rate for projects goes from 30 to 40% (subsidy managed by BPI France). Thus the new Eurostars 2 call for project is launched, which submission deadline is planned on March 13, 2014. Lyonbiopole supports you for EU project set-up thanks to its ETP programme.
Contact: Emilie Romeo - Europe Project Manager
emilie.romeo@lyonbiopole.com

Learn more


01/2014 - 11th call for projects IMI open
 

The 11th call for projects open. It covers several major research themes cut into 8 topics around the effective use of biomarkers and biobanks for personalized medicine, preparation and prevention of zoonoses, prevention of Alzheimer's disease (filing date: 04/08/2014). Several webinars are organized.
Lyonbiopole supports you for EU project set-up thanks to its ETP programme.
Contact: Emilie Romeo - Europe Project Manager
emilie.romeo@lyonbiopole.com

Learn more


01/2014 - ERA-NET calls for European projects

The French National Research Agency is involved in several ERA -NET European funding programs to support research projects in domains as infectious diseases (INFECT-ERA) and antimicrobial resistance (JPI AMR). Two calls for proposals are currently open in this context. INFECT-ERA, the call for proposals is open until 04/02/2014 - find all the information and conditions here and find partners there. JPI in AMR, the first call has been publishedInnovaResistance: Innovative Approaches to address antibacterial resistance(deadline 03/14/2014). Find all the information here and find partners there. The ANR is involved in other ERA-NETs like EuroNanoMed II (nano-medecine), JPND (neurodegenerative diseases), E-RARE 2 (rare disease). SME participation is strongly encouraged in these programs that are an effective way to integrate a long-term network of European players.
Contact: Emilie Romeo, Europe Project Manager -
emilie.romeo@lyonbiopole.com

Learn more


01/2014 - Innovation 2030 Worldwide Innovation Challenge

The Innovation 2030 Commission, chaired by Anne Lauvergeon has defined 7 major ambitions relying on strong, growing, societal expectations, for which innovative solutions are needed. Among these pillars for France's future development is Personalised medicine. The Innovation 2030 Worldwide Innovation Challenge will include 3 phases. The Start-up Phase is opened and will end when 100 innovative projects will be selected. The expected projects must be supported by individual company or consortia. The selected projects must show a strong potential for French economy and correspond to one of the seven goals. The selected project receive a financial subsidy which can reach 200 000€.
Contact: Claudia Chagneau, R&D Projects Manager - claudia.chagneau@lyonbiopole.com

Learn more



A LA UNE
02/11/14 - Let's go for the first Lyonbiopole International mission

From the 10th to the 12th of March, Lyonbiopole will bring a delegation of 10 SMBs to Bio-Europe Spring in Turino (Italy). Bio-Europe Spring is a major partnering event in Europe and is a major place for SMBs to develop their network and such for strategic partner. Lyonbiopole will have a major presence during the event with a common both with its partner from the European project BioXcluster (bioPmed, BioM and BioCat)

Learn more


02/17/14 - New fund rising for Advanced Accelerator Applications

AAAs, specialist in Molecular Nuclear Medicine (MNM), announced today that it had successfully completed a capital increase of €41 million. This capital increase will help fund expansion plans and finance clinical trials of its promising portfolio of Molecular Nuclear Medicine diagnostic and therapeutic products.

Learn more


02/17/14 - Preliminary positive clinical results for Adocia

Adocia announces today positive preliminary results for the first clinical trial on an innovative formulation combining insulin analog Glargine (Lantus®, Sanofi), the gold standard basal insulin, with a rapid-acting insulin analog, Lispro (Humalog®, Eli Lilly) using Adocia's BioChaperone® technology.

Learn more


02/14/14 - ERYTECH welcomes new U.S and European investors in its capital

ERYTECH has been informed that some of its historic institutional shareholders have sold part of their shares to European and American investors specializing in life sciences. A successful operation that allows to diversify geographically and institutionally the shareholder base.

Learn more


02/06/14 - Smartox Biotechnology and Sanofi partner to discover innovative medicines from animal venoms

The two companies announced the signing of a research collaboration aimed at discovering innovative medicines from animal venoms. Snakes, scorpions, spiders and many other species too, are more known for their dangerousness for their therapeutic potential. However, these animals represent a great hope in the field of health.

Learn more


02/04/14 - Cellectis grants genOway sublicense

Cellectis, the specialist in genome engineering and genOway, the specialist in animal models, have announced the signing of an exclusive license agreement allowing genOway become the sole supplier of technology homologous recombination in Cellectis field rodent animal models used for research purposes. 

Learn more


01/29/14 - SynapCell selected to evaluate new treatments against drug epilepsy

The University of Utah and SynapCell signed a one-year contract under the Anticonvulsant Screening Program (ASP) sponsored by the National Institute of Health (NIH) - National Institute of Neurological Disorders and Stroke (NINDS). This partnership will strengthen the existing program at the University of Utah to assess future antiepileptic with a mouse model of mesial temporal lobe epilepsy (MTLE) resistant to existing therapies.

Learn more

 
© Lyonbiopole 2019  |  CREDITS  |  LEGAL NOTICE  |